• SHOP
    • COMBOS
    • TESTIMONIALS
    • CART
    • INGREDIENTS
      • 2-DEOXY-D-GLUCOSE (2DG)
      • ACACIA CYANOPHYLLA FLOWER
      • ACORI GRAMINEI RHIZOMA
      • AEGLE MARMELOS CORREA
      • AGARICUS BLAZEI
      • AGED GARLIC EXTRACT
      • AFRAMOMUM MELEGUETA
      • ALOE ARBORESCENS
      • ALBIZIA
      • ALPINIA OFFICINARUM
      • ALTERNANTHERA SESSILIS
      • AMERICAN GINSENG
      • AMYGDALIN
      • ANACYCLUS PYRETHRUM
      • ANGELICA ARCHANGELICA
      • ANGELICA SINENSIS
      • ANTRODIA
      • APIGENIN
      • ARTICHOKE LEAF
      • ARTOCARPIN
      • AJUGA TURKESTANICA
      • ASHWAGANDHA
      • ASPALATHIN
      • ASTRAGALUS COMPLANATUS
      • AVENA SATIVA
      • BACOPA MONNIERI
      • BAVACHIN
      • BEE POLLEN
      • BETULINIC ACID
      • BOSWELLIC ACID
      • BREVILIN A
      • CAMPESTEROL
      • CAPSAICIN
      • CARCININE
      • CASTICIN
      • CHRYSIN
      • CIANIDANOL
      • CINNAMOMUM ZEYLANICUM
      • CITRULLUS COLOCYNTHIS
      • CITRUS RETICULATA PEEL
      • CODONOPSIS
      • CONJUGATED LINOLEIC ACID
      • COSTUNOLIDE
      • CYANIDIN
      • CUCURBITACIN D
      • DAIDZEIN
      • DECURSIN
      • DELPHINIDIN
      • DIGITALIS PURPREA (DIGOXIN)
      • DIOSMIN
      • ELLAGIC ACID
      • EMBELIN
      • ERIODICTYOL
      • GALLIC ACID
      • GLYCITEIN
      • GLYCYRRHIZIN
      • HYPERFORIN
      • ICARIIN
      • ISORHAMNETIN
      • ISOORIENTIN
      • ISOVITEXIN
      • JACEOSIDIN
      • KAEMPFEROL
      • KIGELIA AFRICANA
      • KURARINONE
      • LEMON BALM
      • LICORICIDIN
      • LIPOIC ACID
      • LUPEOL
      • MAGNOLOL
      • MULBERRY LEAF
      • NARINGENIN
      • NOBILETIN
      • OLEACEIN
      • OLEANOLIC ACID
      • OLIVE OIL
      • ORIDONIN
      • PARTHENOLIDE
      • PHLOROGLUCINOL
      • PHLORIZIN
      • PICEATANNOL
      • PRISTIMERIN
      • PROANTHOCYANIDINS
      • PROCYANIDIN B3
      • PSEUDOLARIC ACID B
      • PTEROSTILBENE
      • RUTIN
      • SOLIDAGO VIRGAUREA
      • TANGERETIN
      • TARAXASTEROL
      • TRICHOSTATIN A
      • WEDELOLACTONE
      • WOGONIN
      • YERBA MATE
    • ABOUT
    • SCIENTIFIC STUDIES
      • ADAPTOGENS
      • ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
      • ADDICTION AND THE BRAIN
      • ADDICTION & STRESS
      • ADDICTION WITHDRAWAL
      • ADIPOCYTE DEDIFFERENTIATION (THE REVERSAL OF FAT FORMATION)
      • ADIPOCYTE DIFFERENTIATION
      • ALLERGIES & CYTOKINES
      • ALDOSTERONE & OBESITY/HYPERTENSION
      • ALZHEIMER’S, DEMENTIA, PARKINSON’S
      • ANTI-ACNE EFFECT OF FLAVONOIDS AND POLYPHENOLS
      • ADVANCED GLYCATION END PRODUCTS (AGES)
      • ADDICTION TREATMENT
      • AMPK
      • ANTI AGING
      • ANTIAGING EFFECTS OF COFFEE
      • ANTI-AGING EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-APOPTOTIC PATHWAYS
      • ANTI ATHEROGENIC
      • ANTI-CANCER EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI CARIOGENIC (Protecting From Tooth Decay)
      • ANTI COVID-19 EFFECTS OF MEDICINAL PLANTS, FLAVONOIDS & POLYPHENOLS
      • ANTI GLYCATIVE
      • ANTI GLYCATION AGENTS
      • ANTI-INFLAMMATORY EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI-VIRAL EFFECTS OF FLAVONOIDS & POLYPHENOLS
      • ANTI WRINKLE AGENTS
      • APOPTOSIS
      • APOPTOSIS IN 3T3-L1
      • AUTOPHAGY
      • BCL-2
      • BCL-W
      • BCL-XL
      • BDNF
      • BECLIN-1 & AUTOPHAGY
      • BH3 MIMETICS
      • BIM aka BCL2L11
      • BMI-1
      • BRASSINOSTEROIDS
      • CALORIE RESTRICTION
      • CALORIE RESTRICTION & LIFESPAN EXTENSION
      • CARBAMYLATION
      • CARBONYL SCAVENGER
      • CARBONYL STRESS
      • CARDIOPROTECTIVE AGENTS
      • CARDIAC GLYCOSIDES
      • CATALASE
      • CELL CYCLE ARREST
      • CENTENARIANS
      • CHOLESTEROL EFFLUX
      • COGNITIVE ENHANCEMENT
      • COLD SHOCK PROTEINS
      • COLD-INDUCIBLE RNA-BINDING PROTEIN (CIRBP) & DNA REPAIR
      • CONDITIONED PLACE PREFERENCE
      • CORTICOTROPIN RELEASING FACTOR
      • CRYOTHERAPY
      • CRYOLIPOLYSIS: FREEZING FAT TO DEATH
      • CYP2E1
      • CYTOKINES IN PAIN, INFLAMMATION & AGING
      • DAF-16
      • DIABETES & CANCER
      • DIHYDROTESTOSTERONE (DHT)
      • DNA METHYLATION & AGING
      • DNA REPAIR
      • DNA REPAIR VIA FLAVONOIDS & POLYPHENOLS
      • ADDICTION & DOPAMINE
      • DRY FASTING AND FLUID RESTRICTION FASTING
      • DYNORPHIN
      • ELLAGITANNINS
      • ENLARGED HEART AND CARDIOMEGALY
      • EPIGENETIC MODIFIERS
      • EPINEPHRINE
      • ERGOGENIC AGENTS (INCREASE ATHLETIC PERFORMANCE)
      • EXCITOXICITY & THE BRAIN
      • EXTRACELLULAR MATRIX STIFFENING (10TH HALLMARK OF AGING)
      • EXTENDS LIFESPAN
      • EXTINCTION TRAINING
      • FASTING BRAIN
      • FASTING CANCER
      • FASTING & CANCER
      • FASTING MIMICKING DIET
      • FEAR EXTINCTION
      • FGF21
      • FLAVONES
      • GABA (γ-AMINOBUTYRIC ACID)
      • GALLOTANNINS
      • GLUCONEOGENESIS
      • GLUTAMATE & BRAIN
      • GLYCATION
      • KLOTHO
      • FASTING, CALORIE RESTRICTION & EXTENDING LIFESPAN
      • FOXO3
      • FOXO4
      • HALLMARKS OF AGING
      • HEPATOPROTECTIVE AGENTS (KEEPING LIVER HEALTHY)
      • HMGB1
      • HORMESIS
      • HPA AXIS
      • HSP70, THE ANTI-AGING PROTEIN
      • HSP90 INHIBITORS
      • HYPERGLYCEMIA
      • HYPERINSULINEMIA
      • HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
      • HYPOCRETIN OREXIN
      • IKK
      • IL-6/STAT3
      • IRISIN
      • ISOFLAVONES
      • IMMUNOSENESCENCE
      • INCREASE PROTEIN SYNTHESIS
      • INFECTOBESITY
      • INFLAMMATION & ANXIETY
      • INFLAMMATION & CANCER
      • INFLAMMATION & DEPRESSION
      • INFLAMMATION & OBESITY
      • INFLAMMAGING
      • INHIBITION OF RENAL GLUCOSE REABSORPTION
      • INSULIN & AGING
      • INSULIN & CANCER: HOW INSULIN LITERALLY PROTECTS CANCER CELLS FROM BEING KILLED
      • INSULIN & MTOR
      • INSULIN & OBESITY
      • INTERMITTENT FASTING
      • JAK INHIBITION ALLEVIATES SASP
      • JNK ACTIVATION PREVENTS PREMATURE SENESCENCE
      • KETONE BODIES
      • KETOGENIC DIET
      • LEYDIG CELL STEROIDOGENESIS
      • LIFESPAN EXTENSION
      • LIPOLYTIC AGENTS
      • LIPID DROPLETS
      • LIPOLYSIS (THE DECOMPOSITION OF BODY FAT)
      • LOWERING CHOLESTEROL THRU FASTING, DIET & MEDICINAL PLANTS
      • MATRIX METALLOPROTEINASES (MMPs)
      • MCL-1
      • MDM2 INHIBITION AS SASP INHIBITOR
      • MEDITERRANEAN DIET
      • MENAQUINONE 4
      • METABOLIC REPROGRAMMING
      • METABOLIC SYNDROME EXTRACT
      • METHIONINE RESTRICTION
      • MITOCHONDRIAL UNCOUPLING
      • MONKEYPOX
      • MSG (MONOSOSODIUM GLUTAMATE)
      • MUSCLE FORCE PRODUCTION
      • MUSCLE ATROPHY (PREVENTING)
      • MYOGENESIS
      • MYOSTATIN INHIBITION
      • MYOSTATIN INHIBITION PRESERVES MUSCLE
      • mTORC2
      • mTOR: THE RAPID AGING PATHWAY
      • NATURAL ANTICOAGULANTS
      • NATURAL AROMATASE INHIBITORS
      • NEUROGENESIS (GROWING NEW BRAIN CELLS)
      • NEUROCHEMISTRY OF ADDICTION
      • NEUROPLASTICITY
      • NEUROINFLAMMATION
      • NEUROPROTECTIVE AGENTS
      • NMDA & ANXIETY & DEPRESSION
      • NMDA RECEPTOR AND FEAR
      • NON-OPIOID ANALGESICS (PLANT BASED)
      • NOOTROPICS
      • NORADRENERGIC
      • NOREPINEPHRINE
      • NRF2: MASTER REGULATOR OF THE AGING PROCESS
      • NF-KB
      • ONCOGENE ACTIVATION INDUCED SENESCENCE
      • OVERNUTRITION
      • OXIDATIVE STRESS & AGING
      • P16INK4A
      • P38MAPK
      • P53: TUMOR SUPRESSOR
      • PERIODONTITIS
      • PHYTOCHEMICALS
      • PHYTOSTEROLS
      • PHYTOSTANOLS
      • PHYTOECDYSTEROIDS
      • PROANTHOCYANIDINS
      • PROTEIN CARBONYLATION
      • POLYAMINES & THEIR EFFECT ON BRAIN (NMDA, DEPRESSION, SUICIDE RISK)
      • PPARY2
      • PREMATURE SENESCENCE
      • PREVENTING SKIN AGING
      • PUFAS
      • PURGATIVES
      • RAPAMYCIN (MTOR INHIBITION)
      • RECEPTOR “Κ OPIOID”
      • RED WINE
      • RENAL (KIDNEY) PROTECTIVE AGENTS
      • REMINERALIZATION OF TEETH
      • REPAIR OF DNA BREAKS “DOUBLE STRAND”
      • RESTORE INSULIN SENSITIVITY
      • SASP & ADIPOSE TISSUE
      • SENESCENT CELLS, SASP & SENOLYTICS
      • SENESCENCE-BETA-GALACTOSIDASE (SA-β-gal or SABG)
      • SGLT2 INHIBITORS
      • SGLT2 INHIBITION FOR LIFESPAN EXTENSION
      • SHBG
      • SIRT1
      • SKELETAL MUSCLE HYPERTROPHY (THE SCIENCE OF BUILDING MUSCLE)
      • SKIN ELASTICITY
      • SKIN PHOTOAGING (Preventing & Repairing)
      • SLEEP DEPRIVATION AS THERAPY FOR DEPRESSION
      • SIRT1 & LONGEVITY
      • SMALLPOX
      • SUGAR & AGING
      • STAR PROTEIN
      • STAT3
      • STEM CELL EXHAUSTION
      • STEM CELL REGENERATION
      • STEM CELL THERAPY
      • STIMULATED LIPOLYSYS
      • STEROIDOGENESIS (THE PRODUCTION OF HORMONES IN BODY)
      • STREPTOCOCCUS MUTANS (MAIN BACTERIA BEHIND TOOTH DECAY)
      • STRESS & AGING
      • STRESS & THE BRAIN
      • TELOMERE SHORTENING & PREMATURE AGING
      • TIME RESTRICTED FEEDING
      • TRAUMATIC BRAIN INJURY (HEALING)
      • TRYPTOPHAN HYDROXYLASE 2
      • VISCERAL ADIPOSITY
    • HOME
    • CONTACT
    • INTERSTELLAR 88/8: EXTREME WEIGHTLOSS PROTOCOL
    • The Ultimate Dry Fasting Resource
    0
    ADIPOCYTE APOPTOSIS (KILLING FAT CELLS)
    February 23, 2021
    HYPOACTIVE SEXUAL DESIRE (WHY PEOPLE HAVE ZERO SEX DRIVE)
    February 23, 2021

    INSULIN PROTECTS CANCER CELLS FROM APOPTOSIS 

    If you are serious about beating and preventing cancer then you want to be secreting as little insulin as possible while remaining as insulin sensitive as possible. That means you only want a tiny amount of insulin being utilized to maintain healthy blood sugar levels.

    How?

    Simple! 22/2 daily intermittent fasting with blends and strict non dairy paleo keto diet.




    SCIENCE

    “We report here that insulin and insulin-like growth factor-I (IGF-I) fully protect HT29-D4 colon carcinoma cell”

    Insulin-like Growth Factor-I Protects Colon Cancer Cells from Death Factor-induced Apoptosis by Potentiating Tumor Necrosis Factor α-induced Mitogen-activated Protein Kinase and Nuclear Factor κB Signaling Pathways

    The role of the insulin-like growth factor I receptor (IGF-IR) in programmed cell death has been investigated in vivo in a biodiffusion chamber, where the extent of cell death could be determined quantitatively. We found that a decrease in the number of IGF-IRs causes massive apoptosis in vivo in several transplantable tumors, either from humans or rodents. Conversely, an overexpressed IGF-IR protects cells from apoptosis in vivo. We also show that the same conditions that in vitro cause only partial growth arrest with a minimum of cell death, induce in vivo almost complete cell death. We conclude that the IGF-IR activated by its ligands plays a very important protective role in programmed cell death, and that its protective action is even more striking in vivo than in vitro

    The Insulin-like Growth Factor I Receptor Protects Tumor Cells from Apoptosis in Vivo

    Insulin‐like growth factor (IGF)‐I protects many cell types from apoptosis. As a result, it is possible that IGF‐I‐responsive cancer cells may be resistant to apoptosis‐inducing chemotherapies. Therefore, we examined the effects of IGF‐I on paclitaxel and doxorubicin‐induced apoptosis in the IGF‐I‐responsive breast cancer cell line MCF‐7. Both drugs caused DNA laddering in a dose‐dependent fashion, and IGF‐I reduced the formation of ladders. We next examined the effects of IGF‐I and estradiol on cell survival following drug treatment in monolayer culture. IGF‐I, but not estradiol, increased survival of MCF‐7 cells in the presence of either drug. Cell cycle progression and counting of trypan‐blue stained cells showed that IGF‐I was inducing proliferation in paclitaxel‐treated but not doxorubicin‐treated cells. However, IGF‐I decreased the fraction of apoptotic cells in doxorubicin‐ but not paclitaxel‐treated cells. Recent work has shown that mitogen‐activated protein kinase (MAPK) and phosphotidylinositol‐3 (PI‐3) kinase are activated by IGF‐I in these cells. PI‐3 kinase activation has been linked to anti‐apoptotic functions while MAPK activation is associated with proliferation. We found that IGF‐I rescue of doxorubicin‐induced apoptosis required PI‐3 kinase but not MAPK function, suggesting that IGF‐I inhibited apoptosis. In contrast, IGF‐I rescue of paclitaxel‐induced apoptosis required both PI‐3 kinase and MAPK, suggesting that IGF‐I‐mediated protection was due to enhancement of proliferation. Therefore, IGF‐I attenuated the response of breast cancer cells to doxorubicin and paclitaxel by at least two mechanisms: induction of proliferation and inhibition of apoptosis. Thus, inhibition of IGF‐I action could be a useful adjuvant to cytotoxic chemotherapy in breast cancer.

    Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects

    Extracellular matrix (ECM) is known to influence the apoptotic response of cells; therefore, the antiapoptotic effect of IGF-1 on breast cancer cells was examined using different ECMs: laminin, collagen IV, or Matrigel. IGF-1 protected cells from apoptosis induced by methotrexate on all ECMs tested, providing the first evidence that IGF-1 protects against apoptosis in three-dimensional culture systems. These data provide the rationale to search for drugs that lower serum IGF-1 in an effort to improve the efficacy of chemotherapeutic drugs for the treatment of breast cancer.

    Insulin-like Growth Factor 1 (IGF-1) Alters Drug Sensitivity of HBL100 Human Breast Cancer Cells by Inhibition of Apoptosis Induced by Diverse Anticancer Drugs

    The extent of apoptosis in vivo is correlated to the decrease in IGF-IR levels and, in turn, tumorigenesis in nude mice is correlated to the fraction of surviving cells. In syngeneic rats, a host response leads to complete inhibition of tumorigenesis. These findings establish, for the first time on a quantitative basis, the relationship between IGF-IR levels and the extent of apoptosis, as well as the relationship between the initial apoptotic event and the time of appearance of transplantable tumors.

    Correlation between Apoptosis, Tumorigenesis, and Levels of Insulin-like Growth Factor I Receptors

    Ketosis was associated inversely with serum insulin levels (P = 0.03).

    Conclusion

    Preliminary data demonstrate that an insulin-inhibiting diet is safe and feasible in selected patients with advanced cancer.

    https://www.sciencedirect.com/science/article/pii/S0899900712001864

    As with insulin, inhibition of IGF-1 signaling has anti-cancer effects.

    The Links Between Insulin Resistance, Diabetes, and Cancer

    The role of the insulin-like growth factor I receptor (IGF-IR) in programmed cell death has been investigated in vivo in a biodiffusion chamber, where the extent of cell death could be determined quantitatively. We found that a decrease in the number of IGF-IRs causes massive apoptosis in vivo in several transplantable tumors, either from humans or rodents. Conversely, an overexpressed IGF-IR protects cells from apoptosis in vivo. We also show that the same conditions that in vitrocause only partial growth arrest with a minimum of cell death, induce in vivo almost complete cell death. We conclude that the IGF-IR activated by its ligands plays a very important protective role in programmed cell death.


     


    Multiple myeloma cell lines express functional receptors for insulin‐like growth factors (IGFs) and several cell types that make up the bone marrow microenvironment produce these cytokines. This suggests that IGFs may play a role in survival and/or expansion of the malignant clone within the marrow in patients with multiple myeloma. We tested the effects of these growth factors on myeloma cells challenged with dexamethasone. Dye exclusion and MTT assays demonstrated that both IGF‐I and IGF‐II protected the 8226 and dox‐40 myeloma cell lines and three primary myeloma cultures from dexamethasone‐induced cytotoxicity in a dose‐dependent fashion. Morphologic studies of target cells and their nuclei as well as DNA electrophoresis confirmed the IGFs afforded protection against dexamethasone‐induced apoptosis. Insulin also protected but was less impressive and required much higher concentrations. IGFs also protected against cycloheximide‐induced apoptosis but were ineffective against serum starvation, topoisomerase II inhibitors, or anti‐fas antibodies. IGF‐induced protection against dexamethasone was not associated with any alteration in quantitative or qualitative expression of BCL‐2, BAX or BCL‐X proteins. These data indicate that insulin‐like growth factors may play a role in maintenance of the malignant clone in patients with myeloma by protecting tumour cells from apoptotic death.

    Resistance of cancer cells against apoptosis induced by death factors contributes to the limited efficiency of immune- and drug-induced de­struction of tumors. We report here that insulin and insulin-like growth factor-I (IGF-I) fully protect HT29-D4 colon carcinoma cells from IFN­g/tumor necrosis factor-a (TNF) induced apoptosis. Survival signaling initiated by IGF-I was not dependent on the canonical survival pathway involving phosphatidylinositol 3*-kinase. In addition, neither pp70S6K nor protein kinase C conveyed IGF-I antiapoptotic function. Inhibition of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) with the MAPK/ERK kinase inhibitor PD098059 and MAPK/p38 with the specific inhibitor SB203580 partially reversed, in a nonadditive manner, the IGF-I survival effect. Inhibition of nuclear factor kB (NF-kB) activity by preventing degradation of the inhibitor of NF-kB (IkB-a) with BAY 11-7082 also blocked in part the IGF-I antiapoptotic effect. However, the complete reversal of the IGF-I effect was obtained only when NF-kB and either MAPK/ERK or MAPK/p38 were inhibited together. Because these pathways are also those used by TNF to signal inflammation and survival, these data point to a cross talk between IGF-I­and TNF-induced signaling. We further report that TNF-induced IL-8 production was indeed strongly enhanced upon IGF-I addition, and this effect was totally abrogated by both MAPK and NF-kB inhibitors. The IGF-I antiapoptotic function was stimulus-dependent because Fas- and IFN/Fas-induced apoptosis was not efficiently inhibited by IGF-I. This was correlated with the weak ability of Fas ligation to enhance IL-8 production in the presence or absence of IGF-I. These findings indicate that the antiapoptotic function of IGF-I in HT29-D4 cells is based on the enhancement of the survival pathways initiated by TNF, but not Fas, and mediated by MAPK/p38, MAPK/ERK, and NF-kB, which act in concert to suppress the proapoptotic signals. In agreement with this model, we show that it was possible to render HT29-D4 cells resistant to Fas-induced apoptosis provided that IGF-I and TNF receptors were activated simul­taneously.


    Diet contributes to over one-third of cancer deaths in the Western world, yet the factors in the diet that influence cancer are not elucidated. A reduction in caloric intake dramatically slows cancer progression in rodents, and this may be a major contribution to dietary effects on cancer. Insulin-like growth factor I (IGF-I) is lowered during dietary restriction (DR) in both humans and rats. Because IGF-I modulates cell proliferation, apoptosis, and tumorigenesis, the mechanisms behind the protective effects of DR may depend on the reduction of this multifaceted growth factor. To test this hypothesis, IGF-I was restored during DR to ascertain if lowering of IGF-I was central to slowing bladder cancer progression during DR. Heterozygous p53-deficient mice received a bladder carcinogen, p-cresidine, to induce preneoplasia. After confirmation of bladder urothelial preneoplasia, the mice were divided into three groups: (a) ad libitum; (b) 20% DR; and (c) 20% DR pius IGF-I (IGF-I/DR). Serum IGF-I was lowered 24% by DR but was completely restored in the IGF-I/DR-treated mice using recombinant IGF-I administered via osmotic minipumps. Although tumor progression was decreased by DR, restoration of IGF-I serum levels in DR-treated mice increased the stage of the cancers. Furthermore, IGF-I modulated tumor progression independent of changes in body weight. Rates of apoptosis in the preneoplastic lesions were 10 times higher in DR-treated mice compared to those in IGF/DR- and ad libitum-treated mice. Administration of IGF-I to DR-treated mice also stimulated cell proliferation 6-fold in hyperplastic foci. In conclusion, DR lowered IGF-I levels, thereby favoring apoptosis over cell proliferation and ultimately slowing tumor progression. This is the first mechanistic study demonstrating that IGF-I supplementation abrogates the protective effect of DR on neoplastic progression.

    1. A chimeric humanized single-chain antibody against the type I Insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of …
    2. A Common Promoter Polymorphism (-23HphI) in Insulin Gene and Susceptibility to Colorectal cancer
    3. A dominant negative mutant of the Insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer
    4. A dominant negative type I Insulin-like growth factor receptor inhibits metastasis of human cancer cells
    5. A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of Insulin analogues
    6. A higher prediagnostic Insulin level is a prospective risk factor for incident prostate cancer
    7. A ketogenic diet reduces central obesity and serum Insulin in women with ovarian or endometrial cancer
    8. A kinome-wide screen identifies the Insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer
    9. A longitudinal study of serum Insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women
    10. A Mechanistic Investigation of Insulin Receptor Substrate 2 Function in Breast cancer Progression
    11. A mendelian randomization study for the potential causal effect of genetically driven Insulin resistance on invasive breast cancer
    12. A nested case-control study of stomach cancer and serum Insulin-like growth factor (IGF)-1, IGF-2 and IGF-binding protein (IGFBP)-3
    13. A New Insulin-Like Growth Factor Binding Protein (mac25) and its Role in Breast cancer and Cell Growth Control
    14. A New Insulin-Like Growth Factor Binding Protein and Its Role in Breast cancer and Cell Growth
    15. A new single nucleotide polymorphism in the Insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese
    16. A novel and selective 3-phosphoinositide-dependent kinase-1 inhibitor, PF-5177624, blocks Insulin-like growth factor-1 induced tumorigenesis in breast cancer cells
    17. A novel autocrine loop involving IGF-II and the Insulin receptor isoform-A stimulates growth of thyroid cancer
    18. A novel mechanism underlying prostate cancer progression: an investigation into the impact of Insulin like growth factors (IGFs), PTEN and IGFBP2 on TMPRSS2 …
    19. A Novel Member of the Insulin-Like Growth Factor Binding Protein Superfamily in Prostate cancer
    20. A novel role for Insulin resistance in the connection between obesity and postmenopausal breast cancer
    21. A novel synthetic human Insulin super promoter for targeting PDX-1-expressing pancreatic cancer
    22. A novel targeted oral Insulin-like growth factor-1 receptor (IGF-1R) inhibitor and its implications for patients with non-small cell lung cancer (NSCLC): A phase I clinical …
    23. A novel unidirectional cross-talk from the Insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells
    24. A phase II study of Insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer
    25. A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, Insulin resistance and colonic inflammation
    26. A pilot safety-feasibility dietary trial targeting Insulin inhibition in ten patients with advanced cancer
    27. A population-based cohort study in Taiwan––use of Insulin sensitizers can decrease cancer risk in diabetic patients?
    28. A preliminary study on the relationship of Insulin-like growth factor-Ⅰ receptor and the carcinogenesis of gastde cancer
    29. A prospective evaluation of Insulin and Insulin-like growth factor-I as risk factors for endometrial cancer.
    30. A prospective study of anthropometric and clinical measurements associated with Insulin resistance syndrome and colorectal cancer in male smokers
    31. A prospective study of C-peptide, Insulin-like growth factor-I, Insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women
    32. A prospective study of Insulin‐like growth factor‐I, IGF‐binding proteins‐1,‐2 and‐3 and lung cancer risk in women
    33. A prospective study of serum Insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk
    34. A prospective study of the Insulin-like growth factor axis in relation with prostate cancer in the SU. VI. MAX trial
    35. A protease resistant Insulin like growth factor binding protein 4 as a treatment for prostate cancer
    36. A review of obesity, Insulin resistance, and the role of exercise in breast cancer patients
    37. A Salutary Tale—Glargine Insulin and cancer risk
    38. A sequence repeat in the Insulin‐like growth factor‐1 gene and risk of breast cancer
    39. A serum-free and Insulin-supplemented cell culture medium ensures fatty acid synthesis gene activation in cancer cells
    40. A Significance of Insulin-like Growth Factors (IGFs) and Insulin-like Growth Factor Binding Proteins (IGFBPs) in Ascites of Ovarian cancer Patients
    41. A study of prostate cancer and its association with dyslipidemia, elevated Insulin levels in blood, and relative Insulin resistance prevalent in South East Asia
    42. A study on Insulin receptor on human hepatocellular cancer cell membrane
    43. A Study on Insulin Resistance and Obesity Among Women at High Risk for Breast cancer Using Cluster Analysis.
    44. A synergistic combination strategy for optimal inhibition of colon cancer stem cells: Simultaneous inhibition of Insulin-like growth factor-1 receptor-AKT-mammalian …
    45. A tale of two receptors: Insulin and Insulin-like growth factor signaling in cancer
    46. A twenty-first century cancer epidemic caused by obesity: the involvement of Insulin, diabetes, and Insulin-like growth factors
    47. A Type I Insulin-Like Growth Factor Receptor Kinase Inhibitor (PQIP) Enhances the Cytotoxicity of Doxorubicin in Human cancer Cell Lines.
    48. A63 DEATH TO THE INFIDELS! CELLULAR APOPTOSIS IN LUNG DISEASE: Insulin Receptor Suppresses Apoptosis In H-292 Human Bronchial Epithelial cancer …
    49. Abdominal visceral and subcutaneous fat increase, Insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy
    50. Aberrant cross-talk and expression of β1 integrins and type 1 Insulin-like growth factor receptor during prostate cancer progression.
    51. Aberrant neuronal cell cycle re-entry: The pathological confluence of Alzheimer’s disease and brain Insulin resistance, and its relation to cancer
    52. Abnormality of growth hormone and Insulin-like growth factor I axis in advanced cancer patients
    53. About the Role of Insulin in the Interaction Between Human Immune and Colon cancer Cells
    54. Absence of down-regulation of Insulin receptors in human breast cancer cells (MCF-7) cultured in serum-free medium: comparison with epidermal growth factor
    55. Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women
    56. Absence of the full-length breast cancer–associated gene-1 leads to increased expression of Insulin-like growth factor signaling axis members
    57. Abstract A10: Insulin resistance’s effect on PSA level for prostate cancer screening
    58. Abstract A33: Utilizing Insulin the treatment of prostate cancer with BKM120 abrogates the therapeutic effect of PI3K pathway inhibition
    59. Abstract A35: Insulin and hypoxia-inducible factor-1 cooperate to increase the viability of pancreatic cancer cells
    60. Abstract A43: Basal expression of Insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a PI3K inhibitor ZSTK474
    61. Abstract A44: Suppression of Insulin-induced fatty acid synthase gene expression and colon cancer cell proliferation by members of the Krüppel-like family of …
    62. Abstract A46: Pharmacodynamic biomarkers for OSI‐906, an Insulin‐like growth factor‐1 receptor (IGF‐1R) tyrosine kinase inhibitor, in cancer patients with advanced …
    63. Abstract A58: Role of Insulin-like growth factor binding protein acid labile complex in ER-PR-Her2+ breast cancer in African American women.
    64. Abstract A61: Smoking modifies the association of Insulin sensitivity biomarkers and pancreatic cancer risk
    65. Abstract B115: Plasma Insulin‐like growth factor 1, binding protein‐3, and risk of prostate cancer: An update from the Health Professional Follow‐up Study 1993–2004
    66. Abstract B129: Preclinical assessment of targeting Insulin‐like growth factor‐2 in bone metastasis from prostate cancer by a human neutralizing antibody (m610) and …
    67. Abstract B22: Modulation of Insulin-like growth factor binding proteins expression in human prostate cancer cells in vitro by american cranberry (Vaccinium …
    68. Abstract B232: Preclinical evaluation of AMG479 a fully human Insulin‐like growth factor receptor‐1 (IGFR1) antibody in ovarian cancer cells
    69. Abstract B39: Modulation of Insulin receptor alternative splicing to develop cancer therapeutics
    70. Abstract B51: The tyrphostin, NT157, suppresses Insulin receptor substrates and augments therapeutic response of prostate cancer
    71. Abstract B59: Race-related differential splicing of the Insulin receptor: A novel target underlying prostate cancer disparities
    72. Abstract B76: Evidence of a causal association between fasting Insulin concentrations and endometrial cancer: A Mendelian randomization analysis
    73. Abstract CN13-04: Obesity, Insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug
    74. Abstract D118: Insulin receptor splicing regulation as a potential target for improved prostate cancer disparity outcomes
    75. Abstract ES9-1: Role for IGF/Insulin signaling in breast cancer
    76. Abstract KN01: Keynote Lecture: PI 3-kinase links obesity, Insulin resistance, and cancer
    77. Abstract LB-187: Dietary energy balance modulation of Kras-and Ink4a/Arf+/-driven pancreatic cancer: the role of Insulin-like growth factor-1.
    78. Abstract LB-28: The IGF/Insulin signaling axis TMPRSS2: ERG and prostate cancer survival.
    79. Abstract LB-329: Use of Insulin sensitizers is associated with better hormone-receptor pattern and improved breast cancer outcomes
    80. Abstract NTOC-097: VACCINATION TARGETING Insulin–LIKE GROWTH FACTOR BINDING PROTEIN–2 (IGFBP–2) IN ADVANCED OVARIAN cancer: SAFETY …
    81. Abstract P1-04-03: Knocking down Suppressor of Cytokine Signaling 7 in breast cancer: The role in Insulin-like Growth Factor-I/Phospholipase Cγ-1 signaling
    82. Abstract P1-07-03: Dual inhibition of IGF1R and Insulin receptor in estrogen receptor positive and triple negative breast cancer and monitoring blockade of metastasis …
    83. Abstract P1-08-10: Insulin resistance and breast cancer incidence and mortality in postmenopausal women
    84. Abstract P1-12-12: The Insulin like growth factor axis and development of tamoxifen resistance in breast cancer
    85. Abstract P1-21-05: A novel long-acting Insulin for cancer therapy reduces xenograft tumor growth
    86. Abstract P2-06-03: Insulin receptor isoform signaling in breast cancer
    87. Abstract P2-07-03: Insulin and breast cancer risk: Novel insights from mammographic density analyses
    88. Abstract P2-16-18: Does Insulin resistance predict complete response in breast cancer patients who underwent neoadjuvant treatment?
    89. Abstract P3-05-13: Overexpression of Insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells
    90. Abstract P3-07-03: Insulin-like growth factor-1 receptor variant associated with decreased breast cancer risk in women with pregnancy-induced hypertension
    91. Abstract P3-07-54: Insulin-like growth factor 1 receptor expression and polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer …
    92. Abstract P3-10-09: Gene deletion of IRS1 inhibited IGF-I, Insulin and estradiol stimulated MCF-7L breast cancer cell growth
    93. Abstract P4-04-07: Heterogeneous gene fusions detected by RNASeq show enrichment of Insulin signaling pathway genes in breast cancer
    94. Abstract P4-06-02: Insulin receptor targeting in breast cancer through yeast surface display
    95. Abstract P4-06-03: Targeting the Insulin receptor with a small peptide (S961) in cancer
    96. Abstract P4-11-02: Worse breast cancer prognosis in Insulin treated diabetic patients-A population based registry study in Sweden
    97. Abstract P4-13-07: Meta-analysis of epidemiological studies of Insulin Glargine and Breast cancer Risk
    98. Abstract P5-07-05: Insulin-like growth factor binding protein-3 is a key component of the breast cancer cell response to DNA-damaging therapy
    99. Abstract P6-09-05: Insulin Resistance, Diabetes Mellitus and Breast cancer Risk in Pre-and Postmenopausal Women: Modification Effect by Moderate Physical …
    100. Abstract P6-12-05: Inducible suppression of Insulin receptor substrate I inhibits IGF-I/Insulin/estradiol dependent cell growth in MCF-7L breast cancer cells
    101. Abstract P6-15-09: Insulin-Like Growth Factor Receptor I (IGF1R) Inhibitors May Be Synergistic with Chemotherapy in Basal Breast cancer
    102. Abstract PD2-07: Insulin receptor substrate (IRS) targeting by the tyrophostin NT157 inhibits breast cancer cell growth
    103. Abstract PD2-5: Low carbohydrate dietary intervention improves Insulin, hormonal levels and inflammatory markers in early stage, postmenopausal breast cancer …
    104. Abstract# 34: Colored potato functional compounds suppress Insulin-like growth factor-1-promoted prostate cancer cell proliferation and elevate apoptosis through …
    105. Abstract# 3421: Her-2 over expression induces metabolic transformation resulting in Insulin-independence in human breast cancer cells
    106. Abstract# 3900: Resveratrol suppresses Insulin-like growth factor-1 promoted colon cancer cell growth via activation of p53/AMPK/TSC-2 and suppression of IGF-1R …
    107. Abstract# 4288: Differential Insulin-like growth factor II (IGF-II) expression may impact breast cancer incidence and survival among African-American and Caucasian …
    108. Abstract# 4404: Possible role of Insulin-like growth factor I in breast cancer proliferation via the CYP1A1 epoxygenase pathway
    109. Abstract# 4874: Insulin, Insulin-like growth factor-I, and risk of breast cancer in postmenopausal women
    110. Abstract# 5048: Deoxycholic acid induces endocytosis of the Insulin-like growth factor-I receptor in colorectal cancer cells
    111. Abstract# 793: Elevated epithelial Insulin-like growth factor expression is a risk factor for lung cancer development
    112. Abstract# 794: Gonadotropin-releasing hormone promotes motility and invasiveness of ovarian cancer cells through transactivation of the Insulin-like growth factor-1 …
    113. Abstract# 795: The role of tissue expressed Insulin-like growth factor (IGF) and the Janus effects of IGFBP-3 in lung cancer development
    114. Abstract# 827: Antitumor effect of diethylstilbestrol (DES) in combination with an Insulin-like growth factor-1 (IGF-1) antibody in preclinical prostate cancer.
    115. Abstract# LB-280: Expression of early placenta Insulin-like growth factor in breast cancer a prerequisite of metastasis forming disseminated tumor cells?
    116. Acanthosis nigricans and severe Insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy
    117. Acquired resistance to tamoxifen is associated with loss of the type I Insulin-like growth factor receptor: implications for breast cancer treatment
    118. Actions of pituitary prolactin and Insulin-like growth factor II in human breast cancer
    119. Activated Insulin-like growth factor (IGF) signaling pathway is a potential therapeutic target for brain metastasis from lung cancer.
    120. Activated α2-macroglobulin binding to human prostate cancer cells triggers Insulin-like responses
    121. Activation of epidermal growth factor receptor/Insulin-like growth factor 1 receptor-β-Catenin-CD44 pathway in periampullary cancer
    122. Activation of Insulin receptors and IGF-1 receptors in COLO-205 colon cancer xenografts by Insulin and Insulin analogue X10 does not enhance growth under …
    123. Activation of Insulin-like growth factor 1 receptor in patients with non-small cell lung cancer
    124. Activation of Insulin-like growth factor 1 receptor regulates the radiation-induced lung cancer cell apoptosis
    125. Activation of Insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
    126. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of Insulin-like growth factor I (IGF-I) in human breast cancer cell lines
    127. Activator protein-2 overexpression accounts for increased Insulin receptor expression in human breast cancer
    128. Adipocyte-released Insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro
    129. Adipocytokines, obesity, and Insulin resistance during combined androgen blockade for prostate cancer
    130. Adipokines and Insulin resistance in young adult survivors of childhood cancer
    131. Adipokines, Insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study
    132. Adiponectin, leptin, and Insulin-pathway receptors as endometrial cancer subtyping markers
    133. Adiponectin: the “unusual suspect” between Insulin resistance and cancer?
    134. Adipose Estrogen and Increased Breast cancer Risk in Obesity: Regulation by Leptin and Insulin
    135. Adiposity and estrogen receptor‐positive, postmenopausal breast cancer risk: Quantification of the mediating effects of fasting Insulin and free estradiol
    136. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes Insulin resistance in β cells and mice
    137. Advance on Insulin-like Growth Factor Binding Protein 2 in Lung cancer and Other Solid Tumors
    138. Advances in Insulin-like growth factor biology and-directed cancer therapeutics
    139. Advances in targeting Insulin-like growth factor signaling pathway in cancer treatment
    140. Affinity for the Insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells.
    141. Age and Insulin levels in breast cancer women and healthy women
    142. Aging and cancer-related loss of Insulin-like growth factor 2 imprinting in the mouse and human prostate
    143. AIB1/SRC-3 deficiency affects Insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice
    144. Aiming for the Insulin-like Growth Factor-1 system in breast cancer therapeutics
    145. AKT activation up-regulates Insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells
    146. Alterations in laminin expression modulate prostate cancer cell behavior through changes in integrin and Insulin-like growth factor receptor actions
    147. Alterations in promoter usage and expression levels of Insulin-like growth factor-II and H19 genes in cervical and endometrial cancer
    148. Alterations in Promoter Usage and Expression Levels of Insulin-like Growth Factor-II and H19 Genes in Cervical andEndometrial cancer
    149. Alterations in serum levels of Insulin‐like growth factors and Insulin‐like growth‐factor‐binding proteins in patients with colorectal cancer
    150. Alterations in the expression of Insulin-like growth factors and their binding proteins in lung cancer
    151. Alterations in the Insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
    152. Alterations of Insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer
    153. Altered expression of Insulin receptor isoforms in breast cancer
    154. Altered expression of Insulin-like growth factor II receptor in human pancreatic cancer.
    155. Altered glucose metabolism and Insulin resistance in cancer-induced cachexia: a sweet poison
    156. Altered Insulin response to glucose in weight-losing cancer patients.
    157. Altered serum levels of Insulin-like growth-factor binding proteins in breast cancer patients
    158. Alternative splicing of Insulin receptor mRNA in cancer and type 2 diabetes mellitus: a review
    159. Alternative tyrosine phosphorylation of signaling kinases according to hormone receptor status in breast cancer overexpressing the Insulin‐like growth factor receptor …
    160. An anti-Insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation
    161. An antibody targeting the type I Insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
    162. An epidemiologic investigation of the roles of plasma lipids, endogenous Insulin, and CYP17 genotype in breast cancer causation.
    163. An evaluation of compliance in cancer patients and non-Insulin dependent diabetics.
    164. An exon variant in Insulin receptor gene is associated with susceptibility to colorectal cancer in women
    165. An HLA-DR–Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2–Specific Immunity in Patients with cancer
    166. An Insulin effect on cytoplasmic estrogen receptor in the human breast cancer cell line MCF-7.
    167. An Insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival
    168. An investigation into the role of the transcription factor ERG and its regulation of the members of the Insulin-growth factor signalling pathway in prostate cancer
    169. An N-terminal fragment of Insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner
    170. Analysis of apoptosis-related gene expression in different serum level of Insulin-like growth factor-1 in mice breast cancer tissue
    171. Analysis of expression profile of gene encoding proteins of signal cascades activated by Insulin-like growth factors in colorectal cancer
    172. Analysis of genomic imprinting of Insulin-like growth factor 2 in colorectal cancer
    173. Analysis of Insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer
    174. ANALYSIS OF Insulin-LIKE GROWTH FACTOR-H IN HUMAN BREAST cancer CELLS
    175. Analyzing structural differences between Insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents
    176. Androgen receptor up-regulates Insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft
    177. Androgens up-regulate the Insulin-like growth factor-I receptor in prostate cancer cells
    178. Animal Models of HyperInsulinemia, Insulin Resistance, and cancer
    179. ANTI-Insulin RESISTANCE TREATMENTS SUPPRESS HER2+ BREAST cancer GROWTH VIA ALTERING METABOLISM
    180. Anti-Insulin-like growth factor strategies in breast cancer
    181. Anti‐Insulin‐like growth factor‐I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines
    182. Anticarcinogenic effect of quercetin by inhibition of Insulin-like growth factor (IGF)-1 signaling in mouse skin cancer
    183. Antimetastatic activity of Insulin-like growth factor binding protein-3 in lung cancer is mediated by Insulin-like growth factor–independent urokinase-type plasminogen …
    184. Antiproliferative actions of Insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells
    185. Antiproliferative and apoptotic effects of a specific anti-Insulin-like growth factor I receptor single chain antibody on breast cancer cells
    186. Antiproliferative and proapoptotic effect of ascorbyl stearate in human pancreatic cancer cells: association with decreased expression of Insulin-like growth factor 1 …
    187. Antiproliferative MCR peptides block physical interaction of Insulin with retinoblastoma protein (RB) in human lung cancer cells
    188. Antisense oligonucleotide targeting of Insulin‐like growth factor‐1 receptor (IGF‐1R) in prostate cancer
    189. Antisense oligonucleotide to Insulin-like growth factor II induces apoptosis in human ovarian cancer AO cell line
    190. Antisense phosphorothioate oligodeoxynucleotide down‐regulation of the Insulin‐like growth factor I receptor in ovarian cancer cells
    191. Antisense RNA to the type I Insulin-like growth factor receptor reversed the transformed phenotype of PC-3 human prostate cancer cell line in vitro
    192. Antisense RNA to the type I Insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
    193. Antitumor effects of a soluble Insulin-like growth factor I receptor in human ovarian cancer cells: advantage of recombinant protein administration in vivo
    194. Antitumor effects of an adenovirus expressing antisense Insulin-like growth factor I receptor on human lung cancer cell lines
    195. Antitumor effects of dual inhibition of the Src and Insulin-like growth factor-1 receptor (IGF-1R) pathways in prostate cancer (PCa).
    196. Apigenin attenuates Insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model
    197. Apigenin modulates Insulin-like growth factor axis: implications for prevention and therapy of prostate cancer
    198. Apigenin suppresses Insulin‐like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study
    199. Apigenin: a promising anticancer agent for the modulation of the Insulin-like Growth Factor (IGF) axis in prostate cancer
    200. Application of Insulin in external treatment of radioactive dermatitis in nasopharyngeal cancer patients with hyperglycemia
    201. Applications of Insulin-like growth factor system in the colorectal cancer
    202. Are dietary influences on the risk of prostate cancer mediated through the Insulin‐like growth factor system?
    203. Are plasma Insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?
    204. Are racial differences in obesity and Insulin resistance related to aggressive breast cancer?
    205. Are sulfonylurea and Insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis
    206. Are the Insulin-like growth factors relevant to cancer?
    207. Are there Relationships between the VDR-FokI Polymorphism and Vitamin D and the Insulin Resistance in Non-melanoma Skin cancer (NMSC) Patients? A Protocol …
    208. Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of Insulin like growth factor-I, its binding protein and …
    209. Aspects of Insulin-like growth factor binding proteins in cancer
    210. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an Insulin-related pathway
    211. Assessing the role of Insulin‐like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating …
    212. Assessment of Insulin-like growth factors and mutagen sensitivity as predictors of lung cancer risk
    213. Association between adiponectin, Insulin resistance, and endometrial cancer
    214. Association between androgen deprivation and serum Insulin levels among Ugandan men with advanced prostate cancer in Mulago Hospital
    215. Association between cognitive impairment patient with solid cancer and Insulin resistance
    216. Association between components of the Insulin-like growth factor system and endometrial cancer risk
    217. Association between components of the Insulin-like growth factor system and epithelial ovarian cancer risk
    218. Association between expression of Insulin resistance (IR) related genes and breast cancer outcome
    219. Association between Insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk
    220. Association between Insulin resistance and breast cancer risk: A Mendelian randomization analysis of data from 228,000 women of European descent
    221. Association between Insulin resistance and luminal B subtype breast cancer in postmenopausal women
    222. Association between Insulin therapy and risk of liver cancer among diabetics: a meta-analysis of epidemiological studies
    223. Association between Insulin-like growth factor 1 gene rs35767 polymorphisms and cancer risk: A meta-analysis
    224. Association between Insulin-like growth factor binding protein-3 promoter polymorphism of− 1590 C> A and lung cancer susceptibility in a Chinese Han population
    225. Association between Insulin-like growth factor receptors & cell density in breast cancer cells
    226. Association between Insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer
    227. Association between Insulin-like growth factor-binding protein-3 polymorphism-202 A/C and the risk of prostate cancer: a meta-analysis
    228. Association between Insulin‐like growth factor‐1 polymorphisms and stomach cancer risk in a Japanese population
    229. Association between polymorphisms of Insulin-like growth factor receptor gene and susceptibility to non-small-cell lung cancer in Fujian Chinese
    230. Association between preoperative serum Insulin levels and lymph node metastasis in endometrial cancer—a prospective cohort study
    231. Association Between Serum Insulin and C-Peptide Levels and Breast cancer: An Updated Systematic Review and Meta-Analysis
    232. Association between serum Insulin and serum lipid substances and breast cancer
    233. Association between the Insulin-like growth factor 1 gene rs2195239 and rs2162679 polymorphisms and cancer risk: a meta-analysis
    234. Association between two functional polymorphisms of Insulin-like growth factor binding protein 3 and colorectal cancer risk in a Chinese population
    235. Association of abnormal glucose metabolism and Insulin resistance in patients with atypical and typical endometrial cancer
    236. Association of adipokines and Insulin, which have a role in obesity, with colorectal cancer
    237. Association of Adipokines and Insulin, Which Have a Role in Obesity, with Colorectal cancer
    238. Association of angiopoietin-2, C-reactive protein and markers of obesity and Insulin resistance with survival outcome in colorectal cancer
    239. Association of biomarkers of Insulin resistance and inflammation with PET CT SUV values in stage IV non-small cell lung cancer (NSCLC).
    240. Association of biomarkers of Insulin resistance and inflammation with skeletal muscle index (SMI) in stage IV non-small cell lung cancer (NSCLC).
    241. Association of circulating Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 with the risk of ovarian cancer: a systematic review and …
    242. Association of Circulating Insulin-like Growth Factors and IGF Binding Protein with Early Cases of cancer Cervix.
    243. Association of dyslipidemia, increased Insulin resistance, and serum CA 15-3 with increased risk of breast cancer in urban areas of North and Central India
    244. Association of fasting serum Insulin and cancer mortality in a healthy population–28-year follow-up of the French TELECOM Study
    245. Association of Insulin Receptor Substrate-1 G972R Variant with Non-small Cell Lung cancer Risk.
    246. Association of Insulin-like growth factor-1 polymorphism and risk of esophageal cancer [J]
    247. Association of Insulin-like growth factor-I receptor polymorphism with colorectal cancer development
    248. Association of Insulin‐like growth‐factor‐I‐induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF‐7 cells
    249. Association of Insulin, Insulin-like growth factor and Insulin-like growth factor binding proteins with the risk of colorectal cancer
    250. Association of Insulin, Metformin, and Statin with Mortality in Breast cancer Patients
    251. Association of markers of Insulin and glucose control with subsequent colorectal cancer risk
    252. Association of metabolic parameters, lipid and cytokine profiling, androgens and Insulin levels in Precancer and Prostate cancer: A cross-sectional study in …
    253. Association of monocyte chemoattractant protein-1 with age, glucose, BMI, Insulin and other breast cancer biomarkers
    254. Association of NAFLD and Insulin Resistance with Non Metastatic Bladder cancer Patients: A Cross-Sectional Retrospective Study
    255. Association of polymorphisms and haplotypes in the Insulin-like growth factor 1 receptor (IGF1R) gene with breast cancer in Korean women
    256. Association of polymorphisms and haplotypes in the Insulin-like growth factor 1 receptor (IGF1R) gene with the risk of breast cancer in Korean women
    257. Association of prognosis with Insulin-like growth factor receptor type I expression in gastric cancer patients: a meta-analysis
    258. Association of prostate cancer risk with Insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging
    259. Association of serum hemoglobin A1c, C‑peptide and Insulin‑like growth factor‑1 levels with the occurrence and development of lung cancer
    260. Association of the Insulin gene polymorphism and colorectal cancer.
    261. Association of visceral adiposity and Insulin resistance with colorectal adenoma and colorectal cancer
    262. Associations between circulating Insulin-like growth factor 1 and mortality in women with invasive breast cancer
    263. Associations between Insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
    264. Associations between plasma Insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
    265. Associations of adipokines & Insulin resistance with sex steroids in patients with breast cancer.
    266. Associations of chronic inflammation, Insulin resistance, and severe obesity with mortality, myocardial infarction, cancer, and chronic pulmonary disease
    267. Associations of hyperglycemia and Insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry
    268. Associations of Insulin and IGFBP-3 with lung cancer susceptibility in current smokers
    269. Associations of Insulin resistance and adiponectin with mortality in women with breast cancer
    270. Associations of Insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB …
    271. Associations of Insulin‐like growth factor and Insulin‐like growth factor binding protein‐3 with mortality in women with breast cancer
    272. Associations of obesity and circulating Insulin and glucose with breast cancer risk: a Mendelian randomization analysis
    273. Associations of serum C-peptide and Insulin-like growth factor binding proteins-3 with breast cancer deaths
    274. Associations of serum isoflavone, adiponectin and Insulin levels with risk for epithelial ovarian cancer: results of a case-control study
    275. AT1-IR-beta association: A new mechanism for the inhibition of Insulin receptor function in breast cancer
    276. Augmentation of response to nab-paclitaxel by inhibition of Insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models
    277. Aurora-A down-regulates IkappaBα via Akt activation and interacts with Insulin-like growth factor-1 induced phosphatidylinositol 3-kinase pathway for cancer …
    278. Authors’ response: Associations of obesity and circulating Insulin and glucose with breast cancer risk
    279. Autoantibodies against Insulin-like growth factor‑binding protein-2 as a serological biomarker in the diagnosis of lung cancer
    280. Autocrine function for Insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells
    281. Autocrine IGF-I/Insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
    282. Autocrine production of Insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells.
    283. Autocrine role of Insulin-like growth factor (IGF)-I in a human thyroid cancer cell line
    284. Azathioprine desensitizes liver cancer cells to Insulin-like growth factor 1 and causes apoptosis when it is combined with bafilomycin A1
    285. Basal expression of Insulin‐like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3‐kinase inhibitor ZSTK474
    286. Baseline Insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients
    287. Beta-cell function and Insulin resistance evaluated by HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance
    288. Bidirectional crosstalk between leptin and Insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal …
    289. Bifurcation analysis of Insulin regulated mTOR signalling pathway in cancer cells
    290. Binding characteristics of pro-Insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to-6
    291. Bioavailable Insulin-like growth factor-I as mediator of racial disparity in obesity-relevant breast and colorectal cancer risk among postmenopausal women
    292. Biochemical and Genetic Markers in Aggressiveness and Recurrence of Prostate cancer: Race-Specific Links to Inflammation and Insulin Resistance
    293. Biochemical characterization of individual human glycosylated pro-Insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer
    294. Biologic roles of estrogen receptor-β and Insulin-like growth factor-2 in triple-negative breast cancer
    295. Biological activity of rainbow trout Ea4‐peptide of the pro‐Insulin‐like growth factor (pro‐IGF)‐I on promoting attachment of breast cancer cells (MDA‐MB‐231) via α2 …
    296. Biological effects of Insulin and its analogs on cancer cells with different Insulin family receptor expression
    297. Biology of Insulin-like growth factor binding protein-4 and its role in cancer
    298. Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast cancer Risk in Chinese Women
    299. Biomarkers of the Insulin-like growth factor pathway predict progression and outcome in lung cancer
    300. Bisphosphonates inhibit Insulin-like growth factor I-induced HIF-1α protein accumulation and VEGF expression in human beast cancer cells
    301. Bisphosphonates suppress Insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells
    302. Blockade of Insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer
    303. Blockade of Insulin-like growth factor signaling induces apoptosis and reduces tumorigenesis and tumor progression in gastric cancer.
    304. Blockade of Insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer
    305. Blockade of the Insulin‐like growth‐factor‐I receptor inhibits growth of human colorectal cancer cells: evidence of a functional IGF‐II‐mediated autocrine loop
    306. Blocking the Insulin-like growth factor-I receptor as a strategy for targeting cancer
    307. Blood Insulin and Insulin sensitivity in breast cancer patients of various ages: the effect of smoking
    308. BMAL1 rewires mitochondrial metabolism and promotes tumor progress of triple negative breast cancer during Insulin resistance
    309. BMS-754807, a small-molecule inhibitor of Insulin-like growth factor-1 receptor/Insulin receptor, enhances gemcitabine response in pancreatic cancer
    310. Body composition changes in rats with experimental cancer cachexia: improvement with exogenous Insulin
    311. Body mass index influences the prognostic impact of combined nuclear Insulin receptor and estrogen receptor expression in primary breast cancer
    312. Body mass index, type 2 diabetes, and Insulin prescription in adolescents and young adults with cancer
    313. Body Size, Physical Activity, Early-Life Energy Restriction, and Associations with Methylated Insulin-like Growth Factor–Binding Protein Genes in Colorectal cancer
    314. Body size, physical activity, genetic variants in the Insulin-like growth factor pathway and colorectal cancer risk
    315. Bone stromal production of Insulin-like growth factor binding protein 5 promotes growth and survival of prostate cancer
    316. Bone turnover markers and Insulin-like growth factor components in metastatic breast cancer: results from a randomised trial of exemestane vs megestrol acetate.
    317. Boostrapping at Several Frequencies Supports Plasma Insulin As a Potential Marker of Breast cancer Risk
    318. Branched chain amino acid suppressed Insulin-initiated proliferation of human cancer cells through induction of autophagy
    319. BRCA1 regulates Insulin‑like growth factor 1 receptor levels in ovarian cancer
    320. Breast cancer Incidence in Diabetes Mellitus Patients on Insulin Glargine Compared with Human Neutral Protamine Hagedorn Insulin Treatment
    321. Breast cancer is associated to impaired glucose/Insulin homeostasis in premenopausal obese/overweight patients
    322. Breast cancer Resistance Protein 1 deficient male mice exhibit impaired estrogen action and Insulin resistance
    323. Breast cancer Risk and Insulin Resistance: Post Genome-Wide Gene–Environment Interaction Study Using a Random Survival Forest
    324. Breast cancer risk factors in relation to estrogen receptor, progesterone receptor, Insulin-like growth factor-1 receptor, and Ki67 expression in normal breast …
    325. Breast cancer Risk in Japanese Women with Special Reference to the Growth Hormone-Insulin-Iike Growth Factor Axis
    326. Breast cancer stem cells cultured without Insulin and effect of estrogen induction
    327. Breast cancer: Worse Prognosis in Insulin-Treated Diabetic Patients
    328. Bufalin inhibited cell proliferation and expression of Insulin-like growth factor 2 and type 1 receptor in human colorectal cancer cells
    329. C-105 Insulin and IGFBP-3 associated with lung cancer susceptibility in current smokers
    330. c‐Src, Insulin‐like growth factor I receptor, G‐protein‐coupled receptor kinases and focal adhesion kinase are enriched into prostate cancer cell exosomes
    331. CA repeat polymorphism in the Insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia
    332. Caffeine and caffeic acid inhibit growth and modify estrogen receptor (ER)-α and Insulin-like growth factor I receptor (IGF-IR) levels in human breast cancer
    333. Caffeine and caffeic acid inhibit growth and modify estrogen receptor and Insulin-like growth factor I receptor levels in human breast cancer
    334. Caloric restriction and Insulin-like growth factors in aging and cancer
    335. Calories and cancer: the role of Insulin-like growth factor-1
    336. Can the Insulin-like growth factors regulate breast cancer growth?
    337. cancer and Insulin-like growth factor-I: a potential mechanism linking the environment with cancer risk
    338. cancer at Insulin injection site
    339. cancer causes metabolic perturbations associated with reduced Insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular …
    340. cancer causes metabolic perturbations associated with reduced Insulin-stimulated glucose uptake in peripheral tissues and impaired muscle microvascular perfusion
    341. cancer cell-derived clusterin modulates the phosphatidylinositol 3′-kinase-Akt pathway through attenuation of Insulin-like growth factor 1 during serum deprivation
    342. cancer incidence among those initiating Insulin therapy with glargine versus human NPH Insulin
    343. cancer incidence and mortality in patients with Insulin-treated diabetes: a UK cohort study
    344. cancer incidence and mortality in patients with type 2 diabetes treated with human Insulin: a cohort study in Shanghai
    345. cancer occurrence in Danish diabetic patients: duration and Insulin effects
    346. cancer risk among Insulin users: comparing analogues with human Insulin in the CARING five-country cohort study
    347. cancer risk associated with Insulin glargine among adult type 2 diabetes patients–a nationwide cohort study
    348. cancer risk factors associated with Insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels in healthy women: effect modification by menopausal status
    349. cancer specific mortality in Insulin-treated type 2 diabetes patients
    350. cancer-drug induced Insulin resistance: innocent bystander or unusual suspect
    351. cancer: A Paradoxical Form of Adaptation? Insulin-Cortisol Dominance and Epigenetic Aspects
    352. Carbohydrate restriction, prostate cancer growth, and the Insulin‐like growth factor axis
    353. Cardiopulmonary fitness, adiponectin, chemerin associated fasting Insulin level in colorectal cancer patients
    354. Cardiovascular risk and Insulin resistance in childhood cancer survivors
    355. CARING (cancer Risk and Insulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants-a systematic review and a …
    356. Case–control study of markers of Insulin resistance and endometrial cancer risk
    357. Castration aggravates Insulin resistance, reduces immune function and improves quality of life of prostate cancer patients
    358. Celecoxib inhibits Insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancer
    359. Cell-associated Insulin-like growth factor-binding proteins inhibit Insulin-like growth factor-I-induced endometrial cancer cell proliferation.
    360. Cell-Cell Adhesion and Insulin-Like Growth Factor I Receptor in Breast cancer
    361. Central and Peripheral Effects of Insulin/IGF‐1 Signaling in Aging and cancer: Antidiabetic Drugs as Geroprotectors and Anticarcinogens
    362. Ceritinib aggravates glycemic control in Insulin-treated patients with diabetes and metastatic ALK-positive lung cancer
    363. Cervical Epidermal Growth Factor‐Receptor (EGF‐R) and Serum Insulin‐Like Growth Factor II (IGF‐II) Levels are Potential Markers for Cervical cancer 1
    364. Cetuximab-induced Insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells
    365. Challenges in modulating Insulin receptor signalling as a therapeutic strategy for cancer
    366. Change of the growth hormone–Insulin-like growth factor-I axis in patients with gastrointestinal cancer: related to tumour type and nutritional status
    367. Changes in glucose, Insulin, and Insulin resistance from presurgery to post adjuvant treatment for breast cancer.
    368. Changes in Insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study
    369. Changes in metabolic risk, Insulin resistance, leptin and adiponectin following a lifestyle intervention in overweight and obese breast cancer survivors
    370. Changes of androgen receptor and Insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
    371. Changes of CD4+ CD25+ Foxp3+ regulatory T cells in the peripheral blood and their correlation with Insulin resistance in different stages of prostate cancer
    372. Characterization of an amino-terminal fragment of Insulin-like growth factor binding protein-3 and its effects in MCF-7 breast cancer cells
    373. Characterization of Insulin regulation of lipid synthesis in MCF-7 human breast cancer cells
    374. Characterization of Insulin-like growth factor 1 receptors (IGF1-R) in human breast cancer cell lines.
    375. Characterization of Insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of …
    376. Characterization of Insulin-like growth factor binding proteins from human breast cancer cells
    377. Characterization of Insulin-like growth factor I (IGF-I) receptors of human breast cancer cells
    378. Characterization of Insulin-like growth factor I binding sites in human bladder cancer cell lines
    379. Characterization of Insulin-like growth factor I receptors and growth effects in human lung cancer cell lines
    380. Characterization of Insulin-like growth factor II receptors in human small cell lung cancer cell lines
    381. Characterization of the Insulin and Transferrin Receptors of Two cancer Cell Lines.
    382. Characterization of the Role of Insulin, IGF-1 and their Receptor Signaling in Proliferation and Survival of Non-Small Cell Lung cancer Cells
    383. Characterization of the Role of Integrins in Insulin Like Growth Factor 1 and 2 (IGF1 and IGF2) Intracellular Signaling In cancer
    384. Characterizing the role of Insulin signalling in advanced prostate cancer
    385. Chemoresistance in pancreatic cancer is driven by stroma-derived Insulin-like growth factors
    386. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to Insulin-like growth factor-I receptor inhibition
    387. Chemosensitization of human prostate cancer using antisense agents targeting the type 1 Insulin‐like growth factor receptor
    388. Cholesterol synthetase DHCR24 induced by Insulin aggravates cancer invasion and progesterone resistance in endometrial carcinoma
    389. Chronic inhibition of mammalian target of rapamycin signaling downregulates Insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and …
    390. Chronic Insulin exposure does not cause Insulin resistance but is associated with chemo-resistance in colon cancer cells
    391. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver cancer Risks: A Nationwide Population-Based Study
    392. Chronological Effect on Insulin and Glycemic Status in cancer Pain Patients
    393. Cigarette smoking exposure, serum Insulin-like growth factors, and cancer risk: A population-based study
    394. Circ_0000003 promotes the proliferation and metastasis of non-small cell lung cancer cells via miR-338-3p/Insulin receptor substrate 2
    395. Circadian aspects of growth hormone–Insulin-like growth factor axis function in patients with lung cancer
    396. Circulating adipokines data associated with Insulin secretagogue use in breast cancer patients
    397. Circulating concentrations of Insulin-like growth factor I and risk of breast cancer
    398. Circulating free Insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case …
    399. Circulating growth factors data associated with Insulin secretagogue use in women with incident breast cancer
    400. Circulating Insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women
    401. Circulating Insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts
    402. Circulating Insulin-like growth factor binding protein-1 and the risk of pancreatic cancer
    403. Circulating Insulin-like growth factor-1 level and ovarian cancer risk
    404. Circulating Insulin-like growth factor-I and binding protein-3 and risk of prostate cancer
    405. Circulating Insulin-like growth factor-I and binding protein-3 and the risk of breast cancer
    406. Circulating Insulin-like growth factor-I in pregnancy and maternal risk of breast cancer
    407. Circulating Insulin-like growth factor-I levels regulate colon cancer growth and metastasis
    408. Circulating Insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case–control study ProtecT
    409. Circulating Insulin‐like growth factor I in relation to melanoma risk in the European Prospective investigation into cancer and nutrition
    410. Circulating Insulin‐like growth factor peptides and prostate cancer risk: a systematic review and meta‐analysis
    411. Circulating Insulin‐like growth factor‐I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank
    412. Circulating interleukin 6 concentrations and Insulin resistance in patients with cancer
    413. Circulating Levels of C-Peptide (Pancreatic Marker of Insulin Secretion) in Cervical cancer
    414. Circulating levels of Insulin-like growth factor 1 and Insulin-like growth factor binding protein 3 associate with risk of colorectal cancer based on serologic and …
    415. Circulating levels of Insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer
    416. Circulating levels of Insulin-like growth factors, their binding proteins, and breast cancer risk
    417. Circulating levels of Insulin‐like growth factor I, its binding proteins‐1,‐2,‐3, C‐peptide and risk of postmenopausal breast cancer
    418. Circulating levels of Insulin‐like growth factor‐I and risk of ovarian cancer
    419. Circulation Insulin-like growth factor peptides and colorectal cancer risk: an updated systematic review and meta-analysis
    420. Classifying the adverse mitogenic mode of action of Insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel
    421. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor Insulin-like growth factor-1
    422. Clinical implications of Insulin-like growth factor 1 system in early-stage cervical cancer
    423. Clinical implications of Insulin-like growth factor I (IGF-I) and II (IGF-II) in stage IIIB cervical cancer.
    424. Clinical prospects of Insulin-like growth factors and IGF binding proteins study in blood serum of ovarian cancer patients
    425. Clinical relevance of Insulin regulatory pathways in non-small cell lung cancer (NSCLC) progression.
    426. Clinical significance of Insulin like growth factor binding protein 3 in patients with lung cancer
    427. Clinical significance of Insulin receptor substrate-I down-regulation in non-small cell lung cancer
    428. Clinical Significance of Insulin-like Growth Factor 1 and Insulin Like Growth Factor Binding Protein 3 in Serum of Patients with Lung cancer [J]
    429. Clinical significance of Insulin-like growth factor 1 receptor (IGF1R) expression in pancreatic cancer
    430. Clinical significance of Insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer
    431. Clinical significance of Insulin-like growth factor-1 receptor expression in stage I non-small-cell lung cancer: immunohistochemical analysis
    432. Clinical significance of Insulin-like growth factor-1 receptor in platinum-based chemotherapy for non-small cell lung cancer
    433. Clinical significance of Insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer
    434. Clinical significance of measurement of serum Insulin-like growth factor Ⅱ levels in patients with cervical cancer [J]
    435. Clinical significance of serum Insulin like growth factor 1 and Insulin like growth factor binding protein 3 in prostate cancer and benign prostatic hyperplasia
    436. Clinical significance of serum Insulin-like growth factor-1 (IGF-1) and Insulinlike growth binding protein-3 (IGFBP-3) in patients with gastric cancer
    437. Clinical significance of serum Insulin-like growth factor-1 (IGF-1) and Insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer
    438. Clinical significance of serum Insulin-like growth factor-1 levels in prostatic cancer
    439. Clinical value of circulating lipocalins and Insulin-like growth factor axis in pancreatic cancer diagnosis
    440. Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic cancer Diagnosis
    441. Clinical value of selected markers of angiogenesis, inflammation, Insulin resistance and obesity in type 1 endometrial cancer
    442. Clinical value of serum level of Insulin-like growth factor-1 diagnosis and treatment for gastric and colorectal cancer
    443. Clinical, haemodynamic, anthropometric, metabolic and Insulin profile of men with high‐stage and high‐grade clinical prostate cancer
    444. Clinicopathological implication of Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) expression in gastric cancer
    445. Clinicopathological significance of Insulin-like growth factor-1 receptor expression in breast cancer.
    446. Cloning of a novel Insulin-regulated ghrelin transcript in prostate cancer
    447. Co-expression of genes of the Insulin-and estrogen signaling system and correlation with clinical parameters in breast cancer patients
    448. Co-inhibition of epidermal growth factor receptor and Insulin-like growth factor receptor 1 enhances radiosensitivity in human breast cancer cells
    449. Co-operativity between oestrogen and Insulin/IGF-I in the control of breast cancer cell proliferation.
    450. Co-targeting HER2/ErbB2 and Insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
    451. Co-targeting Insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer
    452. Co-targeting leptin and Insulin-like growth factor I signaling: dramatic effects of epidermal growth factor receptor inhibitors on triple negative breast cancer cells.
    453. Co-targeting the HER and IGF/Insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease
    454. Co-targeting the Insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines
    455. Cohort study of Insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes
    456. Colon cancer promotion, Insulin resistance and metabolic measures, the role of dietary calcium, vitamin D and fat
    457. Colorectal cancer and pancreatic cancer in patients with type 2 diabetes mellitus. Study of the effect of Insulin therapy
    458. COLORECTAL cancer AND THE GROWTH HORMONE/Insulin-LIKE GROWTH FACTOR-I AXIS
    459. Colorectal cancer mortality and factors related to the Insulin resistance syndrome
    460. Colorectal cancer: Genomic variations in Insulin-like growth factor-1 and-2
    461. Combination of Insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer
    462. Combination therapy approaches to target Insulin-like growth factor receptor signaling in breast cancer
    463. Combination therapy of Insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo
    464. Combination treatment strategies with a focus on rosiglitazone and adriamycin for Insulin resistant liver cancer
    465. Combined in vivo effect of A12, a type 1 Insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors
    466. Combined inhibition of Insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line
    467. Combined treatment with GH, Insulin, and indomethacin alleviates cancer cachexia in a mouse model
    468. Comment on association between Insulin-like growth factor-I (IGF-I) and bone mineral density: further evidence linking IGF-I to breast cancer risk
    469. Comment on: Morden et al. Further Exploration of the Relationship Between Insulin Glargine and Incident cancer: A Retrospective Cohort Study of Older Medicare …
    470. Comment on: Need for Differentiating Diabetes-Specific Mortality from Total Mortality when Comparing Metformin with Insulin Regarding cancer Survival
    471. Comment on: Yang et al.(2010) Associations of Hyperglycemia and Insulin Usage With the Risk of cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry …
    472. Comment on: Yang et al.(2010) Associations of hyperglycemia and Insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes …
    473. Commentary on Validation of the type 1 Insulin-like growth factor receptor as a therapeutic target in renal cancer: Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S …
    474. Comparative Analysis of Insulin-like Growth Factor I and Tumour-associated Antigens in cancer Patients at the Time of Diagnosis
    475. Comparative gene expression and proteomic analysis of IGF-I and Insulin signaling in a large panel of breast cancer cell lines
    476. Comparative study of blood Insulin levels in breast and endometrial cancer patients
    477. Comparative study of Insulin resistance after open and laparoscopic Miles radical resection of rectal cancer
    478. Comparing pioglitazone to Insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights
    479. Comparison of clinical efficacy between laparotomy and laparoscopic radical surgery for gastric cancer and their effects on CRP, CEA and Insulin resistance.
    480. Comparison of telomere length and Insulin‐like growth factor‐binding protein 7 promoter methylation between breast cancer tissues and adjacent normal tissues in …
    481. Comparisons of Endothelial Dysfunction, Inflammation and Insulin Resistance in Differentiated Thyroid cancer Patients According to Their Radioactive Iodine …
    482. Compensatory Insulin receptor (IR) activation on inhibition of Insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer
    483. Compensatory Insulin receptor (IR) activation upon inhibition of Insulin-like growth factor receptor (IGF-1R): Rationale for co-targeting IGF-1R and IR in cancer
    484. Comprehensive analysis of expression patterns of Insulin-like growth factor and Src pathway in patients with non-small cell lung cancer: Two large, independent …
    485. Comprehensive analysis of potential predictive biomarkers for Insulin-like growth factor type-1 receptor (IGF-1R) targeted therapy in pancreatic cancer.
    486. Concentration of Insulin-like growth factor is linked with breast cancer
    487. Concordant loss of imprinting of the human Insulin-like growth factor II gene promoters in cancer
    488. Conditioned media from MCF7 and BT474 breast cancer cells induce Insulin resistance in skeletal muscle myotubes
    489. Conjugated linoleic acid decreases mcf-7 human breast cancer cell growth and Insulin-like growth factor-1 receptor levels
    490. Conjugated linoleic acid downregulates Insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells
    491. Connecting Pathway Errors in the Insulin Signaling Cascade: The Molecular Link to Inflammation, Obesity, cancer, and Alzheimer’s Disease
    492. Constitutive Activation of Insulin Receptor Substrate 1 in Breast cancer: Therapeutic Implication
    493. Consumption of fresh yellow onion ameliorates hyperglycemia and Insulin resistance in breast cancer patients during doxorubicin-based chemotherapy: a …
    494. Control of Expression of Insulin-Like Growth Factor II in Stromal Cells of Breast cancer
    495. Control of luminal type A intrinsic subtype enriched transcription factor network by Insulin: implications of diabetes on breast cancer classification.
    496. Correction: Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD
    497. Correlation among Insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture
    498. Correlation between Body Mass Index, Insulin and Insulin-like Growth Factor-1 in Breast cancer Research [J]
    499. Correlation between Insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer
    500. Correlation of Insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan
    501. Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast cancer in the UAE
    502. Correlation of Insulin-like growth factor-1 (IGF-1) to angiogenesis of breast cancer in IGF-1-deficient mice
    503. Correlation of Insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors …
    504. Correlation of proliferation of pancreatic cancer cells with both saturation index and cell membrane Insulin receptors
    505. Correlation of Proliferation of Pancreatic cancer Cells With Both Saturation Index and Cell Membrane Insulin Receptors
    506. Correlation of Serum Insulin-like Growth Factor 1 with Prostate cancer
    507. Correlation of the sectetion of Insulin and C-peptide in cancer patients
    508. Correlations of Insulin-like growth factor I and Insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer.
    509. Correlations of recurrence after radical surgery for esophageal cancer with glucose-lipid metabolism, Insulin resistance, inflammation, stress and serum p53 …
    510. Corrigendum to” Effects of a home-based exercise program on the Insulin-like growth factor axis in patients operated for colorectal cancer in Sweden: Results from the …
    511. Could exemestane affect Insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on …
    512. Critical appraisal of the recent data published on the link between Insulin and cancer
    513. Cross-talk among estrogen receptor, epidermal growth factor, and Insulin-like growth factor signaling in breast cancer
    514. Cross-talk between the ErbB/HER family and the type I Insulin-like growth factor receptor signaling pathway in breast cancer
    515. Cross-talk between β1 Integrins and Insulin-like Growth Factor I Receptor in Prostate cancer
    516. Crosstalk between epidermal growth factor receptor-and Insulin-like growth factor-1 receptor signaling: implications for cancer therapy
    517. Crosstalk between Insulin receptor and G protein-coupled receptor signaling systems leads to Ca2+ oscillations in pancreatic cancer PANC-1 cells
    518. Crosstalk between Insulin-like growth factor 1 signaling and the estrogen receptor: Implications for breast cancer cell survival
    519. Crosstalk between Insulin/IGF-1 and GPCR signaling systems: a novel target for the anti-diabetic drug metformin in pancreatic cancer
    520. Crosstalk between Runx2 regulatory network and Insulin-like growth factor receptor/Akt signaling pathway in bone metastasis of breast cancer
    521. Crosstalk between the Insulin-like growth factors and estrogens in breast cancer
    522. Crosstalk of the Insulin-like growth factor receptor with the Wnt signaling pathway in breast cancer
    523. Curcumin upregulates Insulin‐like growth factor binding protein‐5 (IGFBP‐5) and C/EBPα during oral cancer suppression
    524. Cyclooxygenase-2 modulates the Insulin-like growth factor axis in non–small-cell lung cancer
    525. Cytotoxic gene therapy for human breast cancer in vitro using thymidine kinase directed by the Insulin promoter
    526. Data report on inflammatory C–C chemokines among Insulin-using women with diabetes mellitus and breast cancer
    527. Dataset on granulopoiesis-and lymphopoiesis-stimulating cytokine levels in Insulin secretagogue users with incident breast cancer
    528. Dataset on growth factor levels and Insulin use in patients with diabetes mellitus and incident breast cancer
    529. De novo lipogenesis is required for Insulin-mediated hepatocarcinogenesis and contributes to human liver cancer prognosis
    530. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on Insulin-like growth factor-1 and …
    531. Decreased expression of Insulin-like growth factor binding protein 3 and its death receptor in association with poor prognosis of the patients with gastric cancer
    532. Decreased expression of the mannose 6-phosphate/Insulin-like growth factor-II receptor promotes growth of human breast cancer cells
    533. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using Insulin: a pilot study
    534. Decreased production of Insulin‐like growth factor‐binding protein (IGFBP)‐6 by transfection of colon cancer cells with an antisense IGFBP‐6 cDNA construct leads to …
    535. Decreased prostate cancer cell migration by inhibition of the Insulin-like growth factor II/Mannose-6-Phosphate receptor
    536. Decreased serum levels of Insulin-like growth factor (IGF)-I in patients with lung cancer: temporal relationship with growth hormone (GH) levels.
    537. Deficiency of proton-sensing ovarian cancer G protein-coupled receptor 1 attenuates glucose-stimulated Insulin secretion
    538. Defining the Critical role for the Insulin-Like Growth Factor-1 (IGF-1) axis in prostate cancer using genetically engineered mouse (GEM) models
    539. Defining the pathway to Insulin-like growth factor system targeting in cancer
    540. Degradation of Insulin‐like growth factor‐I receptor occurs via ubiquitin‐proteasome pathway in human lung cancer cells
    541. Dehydroepiandrosterone, Insulin-like growth factor-I, and prostate cancer
    542. Deleterious Effect of Chemotherapy on Measures of Insulin Resistance in Patients with Newly-Diagnosed Invasive Breast cancer.
    543. Demonstration of Insulin-like growth factor (IGF-I and-II) receptors and binding protein in human breast cancer cell lines
    544. Demonstration of receptors for Insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells.
    545. Depletion of Insulin-like growth factor 1 receptor increases radiosensitivity in colorectal cancer
    546. Detection of Insulin-like growth factor binding proteins (IGFBPs) by li